Two Indonesian Doctors Join in HanAll's Biopharmaceutical Program
- HanAll
Meanwhile, dr. Soraya said that for Indonesia itself, there are not many Fellowship programs for the pharmaceutical sector like this. Even if there are, the program only targets pharmacists, not doctors. "I considered this a wonderful opportunity for me to learn and grow."
In joining this program, many facilities are gotten, such as monthly salary and opportunities for Fellows to learn about the Drug Information Association (DIA).
"Besides monthly salary and active participation in all of HanAll’s meetings with the experts and leaders, I also learned about biopharma company from DIA (Drug Information Association)," dr. Irina explained.
“DIA is a global association that mobilizes life science professionals from all areas of expertise, providing a complete package of learning modules, particularly in the biopharmaceutical area.” She added.
HanAll Biopharma
- HanAll
The Fellowship Program also seeks to minimize the impact of pollution or carbon print. The drug produced by HanAll is acceptable for both humans and animals because it is produced using proper standard laboratory and clinical procedures, stated dr. Soraya.
Afterward, dr. Soraya and dr. Irina will provide the knowledge gained during the Fellowship program and create various types of sustainable and new medicines. So, in the future, Indonesian patients and even the world can experience drug developments according to what is needed in the health sector.
The HanAll Fellowship Program is expected to grow further to become a place for talented doctors. Also, continue to recruit more doctors to participate in the biopharmaceutical industry.
"As a doctor, biopharmaceutical still not to be a favorable field. By joining this program, we can thoroughly explore interesting things about biopharmaceutical and contribute to a greater health impact." dr. Irina stated.
Currently, HanAll is focusing on unreached areas to provide treatment options to patients with rare and intractable diseases by developing innovative therapies in ophthalmology, immunology, oncology, and neurology.
